BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30725328)

  • 41. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
    Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
    Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing.
    Ruf CG; Isbarn H; Wagner W; Fisch M; Matthies C; Dieckmann KP
    Urol Oncol; 2014 Jan; 32(1):33.e1-6. PubMed ID: 23395239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
    Rothermundt C; Thurneysen C; Cathomas R; Müller B; Mingrone W; Hirschi-Blickenstorfer A; Wehrhahn T; Ruf C; Rothschild S; Seifert B; Terbuch A; Grassmugg T; Woelky R; Fankhauser C; Kunit T; Fischer N; Inauen R; Kamradt J; Ziegler K; Haynes A; Jüni P; Gillessen S
    Swiss Med Wkly; 2018; 148():w14640. PubMed ID: 30044478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer.
    Kamran SC; Seisen T; Markt SC; Preston MA; Trinh QD; Frazier LA; Choueiri TK; Martin NE; Nguyen PL; Beard CJ
    Eur Urol; 2018 Feb; 73(2):262-270. PubMed ID: 28687143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large-scale study from the Cancer Registration Committee of the Japanese Urological Association.
    Kawai T; Tanaka Y;
    Int J Urol; 2017 Feb; 24(2):124-128. PubMed ID: 27915468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
    Hentrich M; Debole J; Jurinovic V; Gerl A
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
    Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
    Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.
    Majewski M; Paffenholz P; Ruf C; Che Y; Seidel C; Heinzelbecker J; Schmelz HU; Matthies C; Albers P; Bokemeyer C; Heidenreich A; Pichler M; Nestler T;
    Cancer Med; 2023 Aug; 12(16):16829-16836. PubMed ID: 37392170
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
    Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases.
    Malagón HD; Valdez AM; Moran CA; Suster S
    Am J Surg Pathol; 2007 Sep; 31(9):1356-62. PubMed ID: 17721191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical presentation features of testicular cancer in public hospitals in the Autonomous Community of Madrid, Spain.
    Moreno A; Domínguez A; Alpuente C; Hernándo A; Torres J; Cabrera JA
    Actas Urol Esp; 2015; 39(1):2-7. PubMed ID: 25204991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [French ccAFU guidelines - update 2020-2022: testicular germ cell tumors].
    Murez T; Fléchon A; Savoie PH; Rocher L; Camparo P; Morel-Journel N; Ferretti L; Méjean A
    Prog Urol; 2020 Nov; 30(12S):S280-S313. PubMed ID: 33349427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.
    Fankhauser CD; Roth L; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Moch H; Bode PK; Beyer J; Hermanns T
    BMC Cancer; 2019 Aug; 19(1):802. PubMed ID: 31412792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience.
    Scheckel CJ; Kosiorek HE; Butterfield R; Ho TH; Hilal T
    Oncol Res Treat; 2019; 42(3):95-100. PubMed ID: 30820020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
    Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
    Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
    Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.